FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3022171047> ?p ?o ?g. }

• W3022171047 abstract "Abstract Many patients taking long-acting somatostatin receptor ligand (SRL) injections as first-line medical therapy in acromegaly report limitations, including ongoing disease symptoms especially near injection cycle end and injection site pain. Oral octreotide capsules may provide an alternative to monthly injections. The phase 3 Octreotide capsules versus Placebo Treatment In MultinationAL centers (OPTIMAL) study assessed efficacy and safety of oral octreotide capsules in patients with acromegaly controlled on injectable SRLs. A multinational, randomized, placebo-controlled study was conducted in 56 adult patients with active acromegaly. Eligible patients were ≥ 18 years of age, had evidence of active disease (IGF-I ≥ 1.3 x ULN ≥3 months after last pituitary surgery), and an average IGF-I ≤ 1.0 x ULN on a stable dose of SRL injections (octreotide or lanreotide). At baseline (1 month following the last injection), patients were randomized to receive octreotide capsule or placebo (28 per group) for 36 weeks, followed by an optional open-label oral octreotide extension. The primary endpoint was proportion of patients maintaining biochemical response, defined as IGF-I ≤ 1.0 x ULN (2-value average at weeks 34 and 36). Secondary endpoints included need for rescue with injectable SRLs, GH response (GH &lt; 2.5 ng/mL), and time to loss of IGF-I response (IGF-I &gt;1.0 and ≥ 1.3x ULN for 2 consecutive visits). Safety and tolerability were assessed. The primary endpoint was met, as 58% of patients receiving octreotide capsules maintained IGF-I response vs 19% receiving placebo (P=0.008). Mean IGF-I levels in patients receiving octreotide capsules were within the reference range at treatment end (0.97 x ULN) vs patients receiving placebo (1.69 x ULN). All secondary endpoints were met. Of patients receiving octreotide capsules, 75% completed 36 weeks without need for rescue therapy. However, 68% of the placebo group required rescue therapy. GH response was maintained at week 36 in a significantly larger proportion of patients receiving octreotide capsules than placebo (78% vs 30%; P=0.001). Median time to loss of IGF-I response was not reached by the end of the study for patients receiving octreotide capsules vs 16 weeks for the placebo group (P &lt;0.0001). Five patients in the placebo group had IGF-I levels in the reference range at the end of 36 weeks. Only 2 (7% of placebo group) did not meet loss of response criteria anytime throughout the study. Octreotide capsules were safe and well tolerated; no new/unexpected safety signals were observed. Most patients (55/56) experienced at least one treatment emergent adverse event; most were mild or moderate in intensity. Overall, 90% of patients who completed the trial on octreotide capsules opted to enter the open label extension phase. These phase 3 data demonstrate octreotide capsules to be potentially safe and effective for the treatment of adults with acromegaly." @default.
• W3022171047 created "2020-05-13" @default.
• W3022171047 creator A5003838671 @default.
• W3022171047 creator A5007146249 @default.
• W3022171047 creator A5022118831 @default.
• W3022171047 creator A5024070567 @default.
• W3022171047 creator A5042259942 @default.
• W3022171047 creator A5042807722 @default.
• W3022171047 creator A5045002153 @default.
• W3022171047 creator A5049091175 @default.
• W3022171047 creator A5059278248 @default.
• W3022171047 creator A5066985276 @default.
• W3022171047 creator A5071111551 @default.
• W3022171047 date "2020-04-01" @default.
• W3022171047 modified "2023-09-30" @default.
• W3022171047 title "OR23-07 Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study of Oral Octreotide Capsules in Adult Patients with Acromegaly" @default.
• W3022171047 doi "https://doi.org/10.1210/jendso/bvaa046.211" @default.
• W3022171047 hasPublicationYear "2020" @default.
• W3022171047 type Work @default.
• W3022171047 sameAs 3022171047 @default.
• W3022171047 citedByCount "1" @default.
• W3022171047 countsByYear W30221710472020 @default.
• W3022171047 crossrefType "journal-article" @default.
• W3022171047 hasAuthorship W3022171047A5003838671 @default.
• W3022171047 hasAuthorship W3022171047A5007146249 @default.
• W3022171047 hasAuthorship W3022171047A5022118831 @default.
• W3022171047 hasAuthorship W3022171047A5024070567 @default.
• W3022171047 hasAuthorship W3022171047A5042259942 @default.
• W3022171047 hasAuthorship W3022171047A5042807722 @default.
• W3022171047 hasAuthorship W3022171047A5045002153 @default.
• W3022171047 hasAuthorship W3022171047A5049091175 @default.
• W3022171047 hasAuthorship W3022171047A5059278248 @default.
• W3022171047 hasAuthorship W3022171047A5066985276 @default.
• W3022171047 hasAuthorship W3022171047A5071111551 @default.
• W3022171047 hasBestOaLocation W30221710471 @default.
• W3022171047 hasConcept C126322002 @default.
• W3022171047 hasConcept C141071460 @default.
• W3022171047 hasConcept C142724271 @default.
• W3022171047 hasConcept C168563851 @default.
• W3022171047 hasConcept C197934379 @default.
• W3022171047 hasConcept C203092338 @default.
• W3022171047 hasConcept C204787440 @default.
• W3022171047 hasConcept C27081682 @default.
• W3022171047 hasConcept C2776297358 @default.
• W3022171047 hasConcept C2777433750 @default.
• W3022171047 hasConcept C2778375690 @default.
• W3022171047 hasConcept C2779609023 @default.
• W3022171047 hasConcept C2781025020 @default.
• W3022171047 hasConcept C2984496839 @default.
• W3022171047 hasConcept C71315377 @default.
• W3022171047 hasConcept C71924100 @default.
• W3022171047 hasConcept C90924648 @default.
• W3022171047 hasConceptScore W3022171047C126322002 @default.
• W3022171047 hasConceptScore W3022171047C141071460 @default.
• W3022171047 hasConceptScore W3022171047C142724271 @default.
• W3022171047 hasConceptScore W3022171047C168563851 @default.
• W3022171047 hasConceptScore W3022171047C197934379 @default.
• W3022171047 hasConceptScore W3022171047C203092338 @default.
• W3022171047 hasConceptScore W3022171047C204787440 @default.
• W3022171047 hasConceptScore W3022171047C27081682 @default.
• W3022171047 hasConceptScore W3022171047C2776297358 @default.
• W3022171047 hasConceptScore W3022171047C2777433750 @default.
• W3022171047 hasConceptScore W3022171047C2778375690 @default.
• W3022171047 hasConceptScore W3022171047C2779609023 @default.
• W3022171047 hasConceptScore W3022171047C2781025020 @default.
• W3022171047 hasConceptScore W3022171047C2984496839 @default.
• W3022171047 hasConceptScore W3022171047C71315377 @default.
• W3022171047 hasConceptScore W3022171047C71924100 @default.
• W3022171047 hasConceptScore W3022171047C90924648 @default.
• W3022171047 hasLocation W30221710471 @default.
• W3022171047 hasOpenAccess W3022171047 @default.
• W3022171047 hasPrimaryLocation W30221710471 @default.
• W3022171047 hasRelatedWork W1033900 @default.
• W3022171047 hasRelatedWork W1196491 @default.
• W3022171047 hasRelatedWork W14685745 @default.
• W3022171047 hasRelatedWork W18698962 @default.
• W3022171047 hasRelatedWork W18906171 @default.
• W3022171047 hasRelatedWork W2361742 @default.
• W3022171047 hasRelatedWork W7110257 @default.
• W3022171047 hasRelatedWork W7878281 @default.
• W3022171047 hasRelatedWork W8376576 @default.
• W3022171047 hasRelatedWork W8820293 @default.
• W3022171047 isParatext "false" @default.
• W3022171047 isRetracted "false" @default.
• W3022171047 magId "3022171047" @default.
• W3022171047 workType "article" @default.